Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue 4, 2001, Pages 203-209

  Gouni Berthold, I ^a   Berthold, H K ^a   Weber, A A ^a   Seul, C ^a   Vetter, H ^a   Sachinidis, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Low density lipoprotein; MAP kinase; Oral antidiabetic drugs; Rosiglitazone; Troglitazone

Indexed keywords

GROWTH FACTOR; LIGAND; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; BLOTTING, WESTERN; CELL DIVISION; CHROMANS; DNA; ENZYME ACTIVATION; HYPOGLYCEMIC AGENTS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KINETICS; LIPOPROTEINS, LDL; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, INBRED WKY; SIGNAL TRANSDUCTION; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0034967630     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15107     Document Type: Article

References (44)

1. 2+ mobilization and cell proliferation in vascular smooth muscle cells
2. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
3. The smooth muscle cell in culture
4. The mitogen-activated protein kinase signal transduction pathway
5. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
6. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats
7. MEKKs, GCKs, MLKs, PAKs, TAKs and tpls: Upstream regulators of the c-Jun amino-terminal kinases?
8. Growth factors and mitogen-activated protein kinases
9. Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE
10. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation
11. PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
12. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
13. Expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma) in rat aortic smooth muscle cells
14. Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: Mediation via pertussis toxin-sensitive G proteins and association with oxidized LDL-induced cytotoxity
15. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes
16. Native low-density lipoprotein (LDL) induces the expression of the early-growth response gene-1 in human umbilical arterial endothelial cells
17. Expression and function of PPARgamma in rat and human vascular smooth muscle cells
18. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
19. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma)
20. Lipoproteins increase growth and mitogen stimulated arterial smooth muscle cell
21. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
22. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
23. Increased expression and acticvation of stress-activated protein kinases/c-Jun NH (2)-terminal protein kinases in atherosclerotic lesions coincide with p53
24. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
25. Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes
26. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
27. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
28. Separation of plasma lipoproteins by density-gradient ultracentrifugation
29. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
30. The pathogenesis of atherosclerosis: A perspective for the 1990s
31. Thromboxane A2 and vascular smooth muscle cell proliferation
32. Lipoproteins induce expression of the early growth response gene-1 in vascular smooth muscle cells from rat
33. Cholesterol enhances platelet-derived growth factor-BB-induced [Ca2+]i and DNA synthesis in rat aortic smooth muscle cells
34. Novel cellular activities for low-density lipoprotein in vascular smooth muscle cells
35. The growth-promoting effect of low-density lipoprotein may be mediated by a pertussis toxin-sensitive mitogen-activated protein kinase pathway
36. Peroxisome proliferator-activated receptors, orphans with ligands and functions
37. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
38. Replication of smooth muscle cells in vascular disease
39. Low density lipoprotein enhances the thrombin-induced growth of vascular smooth muscle cells
40. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
41. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
42. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
43. Activation of mitogen-activated protein kinase by oxidized low-density lipoprotein in canine cultured vascular smooth muscle cells
44. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cell